Xxxyyyy Novar

CORPORATE CITIZENSHIP KEY PERFORMANCE INDICATORS
Indicator 2011 2010 2009 2008 2007

Economic 1 Net sales in USD billions Net income in USD billions; % of net sales Core Research & Development inUSD billions; % of net sales Purchased goods and services 2 in USD billions; % of net sales Personnel costs in USD billions; % of net sales Taxes in USD billions; % of net income before taxesDividends in USD billions; % of net income attributable to Novartis shareholders 3 Cash returned to shareholders via second-line share repurchases in USD billions; % of Group total net income Share price atyear-end (CHF) Patients 4 Access to medicine: value in USD millions Access to medicine: number of patients reached in millions People and Communities Full-time equivalent positions Resignations (incl.retirements); separations; hiring (% of associates) Women in management 5: % of management; % of Board of Directors Number of associate nationalities Lost-time injury and illness rate (per 200 000hours worked) 1,6,7 Total recordable case rate (per 200 000 hours worked) 1,6,7,8 Transportation-related injuries leading to lost time 1,6,7 Environment 1,7,9 Contact water use, excluding cooling water(million m3) Energy use (million GJ), on site and purchased GHG emissions, Scope 1 vehicles (1000 t) GHG emissions, total Scope 1, including vehicles, and Scope 2 (1000 t) Total operational waste notrecycled (1000 t), hazardous and non-hazardous Ethical Business Conduct Novartis associates trained on Code of Conduct via e-learning course 10 Associates completing certification on Code of ConductCases of misconduct reported; substantiated 11 Dismissals and resignations related to misconduct 11 Total number of suppliers Suppliers informed of Novartis Third-Party Guidelines (annual sales of morethan USD 100 000 and not requiring a self-declaration) Suppliers to confirm key standards (self-declaration) 14 419 33 080 1 522; 825 384 225 500 45 203 3 926 18 302 29 835 1 236; 743 608 241 365 39...